Characteristics of lesions/areas of (yet) unknown clinical relevance that were detected at baseline screening (n=10)
| Lesion no. | Case no. | Genetic background (no. of affected family members with PDAC) | Lesion | Detection test | Management | Pathology report | Outcome |
|---|---|---|---|---|---|---|---|
| #1 | 1 | FPC (2) | Unclear lesion 11 mm in body of pancreas | EUS | Interval 3 months | NA | No abnormality detected at FU 3 and 12 months |
| #2 | 2 | CDKN2A (3) | Unclear lesion 5 mm in head of pancreas | EUS | Interval 6 months | NA | At FU 6 and 12 months characterised as duct ectasia |
| #3 | 3 | CDKN2A (0) | Unclear lesion 9 mm in head of pancreas | MRI | Standard FU at 12 months | NA | No abnormality detected at FU 12 months |
| #4 | 4 | CDKN2A (5) | Unclear lesion 5 mm in tail of pancreas | EUS | Interval 3 months | NA | Lesion unchanged at FU 3 and 12 months, characterised as pronounced lobule |
| #5 | 5 | FPC (3) | Unclear lesion 5 mm in body of pancreas | EUS | Interval 3 months | NA | Lesion unchanged at FU 3 and 12 months |
| #6 | 6 | CDKN2A (2) | Unclear lesion 2 mm in head of pancreas | EUS | Standard FU at 12 months | NA | Lesion unchanged at FU 12 months |
| #7 | 7 | BRCA2 (2) | Unclear lesion 5 mm in head of pancreas | MRI | Standard FU at 12 months | NA | No abnormality detected at FU 12 months, lesion characterised as blood vessel |
| #8 | 8 | FPC (4) | Unclear lesions 5 mm in body of pancreas | EUS | Interval 3 months | Multifocal PanIN2 | Lesion unchanged at FU 3 months, at FU 12 months solid component → resection |
| #9 | 8 | FPC (4) | Unclear lesions 5 mm in tail of pancreas | EUS | Interval 3 months | Multifocal PanIN2 | Lesion unchanged at FU 3 months, at FU 12 months solid component → resection |
| #10 | 9 | FPC (3) | Unclear lesion 3 mm in body of pancreas | EUS | Interval 3 months | NA | Lesion unchanged at FU 3 months, characterised as cyst at FU 12 months |
EUS, endoscopic ultrasonography; FPC, familial pancreatic cancer; FU, follow-up; PanIN, pancreatic intraepithelial neoplasia.